Drug Profile
Indimitecan - Gibson Oncology
Alternative Names: LMP-776; NSC-725776Latest Information Update: 24 Feb 2022
Price :
$50
*
At a glance
- Originator National Cancer Institute (USA); Purdue University
- Developer National Cancer Institute (USA)
- Class Antineoplastics; Imidazoles; Isoquinolines; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
- No development reported Lymphoma
Most Recent Events
- 24 Feb 2022 Indimitecan - Gibson Oncology is available for licensing as of 24 Feb 2022. https://gibsononcology.com/our-pipeline/
- 17 Jan 2022 Indimitecan is still in phase I trials for Solid tumours in USA (Gibson Oncology pipeline, January 2022)
- 06 Sep 2018 Gibson Oncology acquires indenoisoquinolines from Linus Oncology